Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
News|Articles|April 4, 2025
Recapping INTERPHEX 2025: Pharma Looks Toward the Future
Author(s)Patrick Lavery
The yearly convention in New York City showcased new and emerging technologies and gave participating exhibitors a chance to unveil their strategies for the second half of the 2020s.
Advertisement
Advertisement
INTERPHEX 2025, an annual global pharmaceutical and biotechnology event, took place at the Jacob K. Javits Convention Center in New York City from April 1–3, 2025. Pharmaceutical Technology® Group covered the conference from multiple angles, publishing news about company offerings and exhibits, attending presentations and lecture sessions, conducting on-site interviews with subject matter experts and key opinion leaders, and keeping a finger on the pulse of breaking developments.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
Advertisement
Advertisement